A group of rare autoimmune neurological disorders characterized by antibodies targeting neuronal surface or synaptic proteins, leading to subacute onset of neuropsychiatric symptoms including seizures, memory impairment, psychosis, movement disorders, and autonomic dysfunction. Anti-NMDA receptor encephalitis is the most common and best-characterized subtype. Early immunotherapy is associated with improved outcomes.
Ask a research question about Autoimmune Encephalitis. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Autoimmune Encephalitis
creation_date: "2026-03-06T00:00:00Z"
updated_date: "2026-05-08T16:21:17Z"
category: Autoimmune
disease_term:
preferred_term: autoimmune encephalitis
term:
id: MONDO:0020640
label: autoimmune encephalitis
parents:
- Neurological Disease
- Autoimmune Disease
description: >-
A group of rare autoimmune neurological disorders characterized by
antibodies targeting neuronal surface or synaptic proteins, leading to
subacute onset of neuropsychiatric symptoms including seizures, memory
impairment, psychosis, movement disorders, and autonomic dysfunction.
Anti-NMDA receptor encephalitis is the most common and best-characterized
subtype. Early immunotherapy is associated with improved outcomes.
has_subtypes:
- name: Anti-NMDA Receptor Encephalitis
description: >-
The most common form, predominantly affecting young women and children.
Caused by antibodies against the GluN1 subunit of the NMDA receptor.
Progresses through phases: prodromal, psychiatric, movement disorder,
autonomic instability, and recovery. Associated with ovarian teratomas
in a significant proportion of adult women.
evidence:
- reference: PMID:31326280
reference_title: "An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The disease is more prevalent in women (with a female to male ratio of
around 8:2) and about 37% of patients are younger than 18 years at
presentation of the disease. Tumours, usually ovarian teratoma, and
herpes simplex encephalitis are known triggers of NMDAR autoimmunity.
explanation: >-
Confirms female predominance and ovarian teratoma association in
anti-NMDAR encephalitis.
- name: Anti-LGI1 Encephalitis
description: >-
Limbic encephalitis caused by antibodies against leucine-rich
glioma-inactivated 1 (LGI1). Predominantly affects older men. Presents
with faciobrachial dystonic seizures, memory impairment, and
hyponatremia.
- name: Anti-CASPR2 Encephalitis
description: >-
Caused by antibodies against contactin-associated protein-like 2
(CASPR2). Presents with limbic encephalitis, neuromyotonia, or
Morvan syndrome. Associated with thymoma.
pathophysiology:
- name: Antibody-Mediated NMDA Receptor Internalization
description: >-
In anti-NMDA receptor encephalitis, IgG antibodies crosslink and
internalize NMDA receptors, reducing receptor density at synapses and
disrupting glutamatergic neurotransmission. This leads to disinhibition
of excitatory pathways and the characteristic neuropsychiatric
manifestations. The antibodies serve as both a diagnostic marker and
a pathogenic mediator that alters NMDAR-related synaptic transmission.
cell_types:
- preferred_term: Neuron
term:
id: CL:0000540
label: neuron
- preferred_term: B cell
term:
id: CL:0000236
label: B cell
biological_processes:
- preferred_term: Glutamate receptor signaling pathway
term:
id: GO:0007215
label: glutamate receptor signaling pathway
- preferred_term: Immune response
term:
id: GO:0006955
label: immune response
evidence:
- reference: PMID:31326280
reference_title: "An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
autoantibodies serve as a diagnostic marker and alter NMDAR-related
synaptic transmission
explanation: >-
Confirms antibodies both diagnose and directly cause disease by
altering NMDAR synaptic transmission.
- name: Intrathecal Antibody Production
description: >-
B cells and plasma cells within the central nervous system produce
pathogenic antibodies intrathecally. Germinal center-like structures
may form in the meninges, sustaining local antibody production.
This explains why serum antibody titers do not always correlate
with disease severity.
cell_types:
- preferred_term: Plasma cell
term:
id: CL:0000786
label: plasma cell
- name: IL-6 Production by Activated Immune Cells
description: >-
Activated CD4+ T cells, macrophages, and B cells in autoimmune
encephalitis secrete interleukin-6 (IL-6). Multi-omics profiling of AIE
cerebrospinal fluid identifies the IL6-STAT3 axis as a candidate
therapeutic target, implicating elevated IL-6 production as an upstream
contributor to immune-inflammatory pathology.
cell_types:
- preferred_term: CD4-positive, alpha-beta T cell
term:
id: CL:0000624
label: CD4-positive, alpha-beta T cell
- preferred_term: Macrophage
term:
id: CL:0000235
label: macrophage
- preferred_term: B cell
term:
id: CL:0000236
label: B cell
biological_processes:
- preferred_term: Interleukin-6 production
term:
id: GO:0032635
label: interleukin-6 production
modifier: INCREASED
downstream:
- target: STAT3 Activation via JAK-STAT Cascade
description: >-
IL-6 binding to the IL-6 receptor complex triggers JAK-mediated
phosphorylation and activation of STAT3 in responding cells.
causal_link_type: DIRECT
- name: STAT3 Activation via JAK-STAT Cascade
description: >-
IL-6 receptor engagement activates the JAK-STAT cascade, driving STAT3
phosphorylation and nuclear translocation. CSF multi-omics analysis
nominates the IL6-STAT3 axis as a potential therapeutic target in AIE,
consistent with STAT3 acting as a hub that converts upstream IL-6 signal
into a pro-inflammatory transcriptional programme.
biological_processes:
- preferred_term: JAK-STAT cascade
term:
id: GO:0007259
label: cell surface receptor signaling pathway via JAK-STAT
modifier: INCREASED
evidence:
- reference: PMID:42162799
reference_title: "Multi-omics profiling of cerebrospinal fluid in autoimmune encephalitis: insights into pathogenesis and therapeutic targets."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Integrated multi-omics analysis validated these findings and identified
several potential therapeutic targets for AIE, including the IL6-STAT3
axis.
explanation: >-
CSF multi-omics in 65 AIE patients vs controls identified the IL6-STAT3
axis among the candidate therapeutic targets, supporting its inferred
role in AIE immune-inflammatory pathology.
downstream:
- target: Pro-inflammatory Cytokine Amplification
description: >-
Activated STAT3 drives transcription of additional pro-inflammatory
cytokines, amplifying the inflammatory response.
causal_link_type: DIRECT
- name: Pro-inflammatory Cytokine Amplification
description: >-
STAT3-driven transcription amplifies the production of pro-inflammatory
cytokines, broadening immune activation beyond the initial IL-6 signal.
biological_processes:
- preferred_term: Cytokine production
term:
id: GO:0001816
label: cytokine production
modifier: INCREASED
- preferred_term: Inflammatory response
term:
id: GO:0006954
label: inflammatory response
modifier: INCREASED
downstream:
- target: CNS Immune Cell Infiltration
description: >-
Cytokine-rich milieu promotes leukocyte chemotaxis across the
blood-brain barrier into the central nervous system.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- >-
Cytokine-induced adhesion molecule upregulation on cerebral
endothelium
- Chemokine gradients across the blood-brain barrier
- name: CNS Immune Cell Infiltration
description: >-
Pro-inflammatory cytokines and chemokines recruit leukocytes (T cells,
macrophages, B cells) across the blood-brain barrier into the central
nervous system parenchyma and meninges.
cell_types:
- preferred_term: CD4-positive, alpha-beta T cell
term:
id: CL:0000624
label: CD4-positive, alpha-beta T cell
- preferred_term: Macrophage
term:
id: CL:0000235
label: macrophage
- preferred_term: B cell
term:
id: CL:0000236
label: B cell
biological_processes:
- preferred_term: Leukocyte chemotaxis
term:
id: GO:0030595
label: leukocyte chemotaxis
modifier: INCREASED
downstream:
- target: Neuroinflammation and Neuronal Dysfunction
description: >-
Infiltrating immune cells release cytokines and effector molecules
within the CNS, producing sustained neuroinflammation and impairing
neuronal function.
causal_link_type: DIRECT
- name: Neuroinflammation and Neuronal Dysfunction
description: >-
Sustained CNS inflammation driven by infiltrating leukocytes and
intrathecal cytokine signaling contributes to neuronal dysfunction
underlying the neuropsychiatric manifestations of AIE. This node
integrates the downstream consequence of the IL6-STAT3 axis with
antibody-mediated synaptic dysfunction already modelled above.
biological_processes:
- preferred_term: Inflammatory response
term:
id: GO:0006954
label: inflammatory response
modifier: INCREASED
phenotypes:
- category: Neurological
name: Seizures
frequency: VERY_FREQUENT
diagnostic: true
notes: >-
Seizures occur in the majority of patients and may be the presenting
symptom. Can be focal or generalized.
evidence:
- reference: PMID:31326280
reference_title: "An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
some patients with rapidly progressive psychiatric symptoms or
cognitive impairment, seizures, abnormal movements, or coma of unknown
cause, had an autoimmune disease
explanation: >-
Seizures identified as a key presenting feature of anti-NMDAR
encephalitis.
phenotype_term:
preferred_term: Seizure
term:
id: HP:0001250
label: Seizure
- category: Psychiatric
name: Psychosis
frequency: VERY_FREQUENT
notes: >-
Acute psychiatric symptoms including hallucinations, delusions,
agitation, and catatonia. Often leads to initial psychiatric
hospitalization before the autoimmune diagnosis is recognized.
evidence:
- reference: PMID:31326280
reference_title: "An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
some patients with rapidly progressive psychiatric symptoms or
cognitive impairment, seizures, abnormal movements, or coma of unknown
cause, had an autoimmune disease
explanation: >-
Rapidly progressive psychiatric symptoms are a hallmark presentation
of autoimmune encephalitis.
phenotype_term:
preferred_term: Psychosis
term:
id: HP:0000709
label: Psychosis
- category: Neurological
name: Memory Impairment
frequency: VERY_FREQUENT
notes: >-
Short-term memory loss is a hallmark, particularly prominent in
anti-LGI1 encephalitis where it may be the predominant feature.
evidence:
- reference: PMID:31326280
reference_title: "An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
some patients with rapidly progressive psychiatric symptoms or
cognitive impairment, seizures, abnormal movements, or coma of unknown
cause, had an autoimmune disease
explanation: >-
Cognitive impairment (including memory) is a key presenting feature.
phenotype_term:
preferred_term: Memory impairment
term:
id: HP:0002354
label: Memory impairment
- category: Neurological
name: Dyskinesia
frequency: FREQUENT
notes: >-
Orofacial dyskinesias and choreoathetoid movements are characteristic
of anti-NMDA receptor encephalitis.
evidence:
- reference: PMID:31326280
reference_title: "An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
some patients with rapidly progressive psychiatric symptoms or
cognitive impairment, seizures, abnormal movements, or coma of unknown
cause, had an autoimmune disease
explanation: >-
Abnormal movements (dyskinesias) are part of the diagnostic spectrum.
phenotype_term:
preferred_term: Dyskinesia
term:
id: HP:0100660
label: Dyskinesia
- category: Neurological
name: Abnormality of the Autonomic Nervous System
frequency: FREQUENT
notes: >-
Autonomic instability including cardiac dysrhythmias, blood pressure
fluctuations, central hypoventilation, and hyperthermia. Can be
life-threatening.
phenotype_term:
preferred_term: Abnormality of the autonomic nervous system
term:
id: HP:0002270
label: Abnormality of the autonomic nervous system
- category: Constitutional
name: Fever
frequency: FREQUENT
notes: >-
Low-grade fever is common in the prodromal phase.
phenotype_term:
preferred_term: Recurrent fever
term:
id: HP:0001954
label: Recurrent fever
treatments:
- name: First-Line Immunotherapy
description: >-
Combination of corticosteroids, intravenous immunoglobulin, and/or
plasma exchange. Approximately 53% of patients improve within 4 weeks
of first-line treatment or tumor removal.
evidence:
- reference: PMID:23290630
reference_title: "Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
472 (94%) underwent first-line immunotherapy or tumour removal,
resulting in improvement within 4 weeks in 251 (53%).
explanation: >-
Large observational cohort showing majority of patients receive
first-line immunotherapy with about half responding within 4 weeks.
treatment_term:
preferred_term: immunotherapy
term:
id: MAXO:0001002
label: immunotherapy procedure
- name: Rituximab
description: >-
Second-line immunotherapy for patients who fail first-line treatment.
Depletes CD20+ B cells to reduce antibody production. Patients who
receive second-line immunotherapy have significantly better outcomes
than those who do not.
evidence:
- reference: PMID:23290630
reference_title: "Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Of 221 patients who did not improve with first-line treatment, 125
(57%) received second-line immunotherapy that resulted in a better
outcome (mRS 0-2) than those who did not
explanation: >-
Second-line immunotherapy (rituximab/cyclophosphamide) significantly
improves outcomes in treatment-refractory patients.
- reference: PMID:31326280
reference_title: "An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
About 80% of patients improve with immunotherapy and, if needed,
tumour removal, but the recovery is slow.
explanation: >-
Overall 80% response rate to immunotherapy including second-line
agents.
treatment_term:
preferred_term: rituximab therapy
term:
id: NCIT:C15986
label: Pharmacotherapy
- name: Tumor Resection
description: >-
Removal of associated tumors (ovarian teratoma in anti-NMDA receptor
encephalitis, thymoma in anti-CASPR2) is critical for treatment
response and reduces relapse risk.
evidence:
- reference: PMID:31326280
reference_title: "An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
About 80% of patients improve with immunotherapy and, if needed,
tumour removal, but the recovery is slow.
explanation: >-
Tumor removal is part of the standard treatment approach for
autoimmune encephalitis with associated tumors.
treatment_term:
preferred_term: surgical procedure
term:
id: MAXO:0000004
label: surgical procedure
datasets:
references:
- reference: DOI:10.1017/cjn.2024.16
title: Canadian Consensus Guidelines for the Diagnosis and Treatment of Autoimmune Encephalitis in Adults
found_in:
- Autoimmune_Encephalitis-deep-research-falcon.md
findings:
- statement: Autoimmune encephalitis is increasingly recognized as a neurologic cause of acute mental status changes with similar prevalence to infectious encephalitis.
supporting_text: Autoimmune encephalitis is increasingly recognized as a neurologic cause of acute mental status changes with similar prevalence to infectious encephalitis.
evidence:
- reference: DOI:10.1017/cjn.2024.16
reference_title: Canadian Consensus Guidelines for the Diagnosis and Treatment of Autoimmune Encephalitis in Adults
supports: SUPPORT
evidence_source: OTHER
snippet: Autoimmune encephalitis is increasingly recognized as a neurologic cause of acute mental status changes with similar prevalence to infectious encephalitis.
explanation: Deep research cited this publication as relevant literature for Autoimmune Encephalitis.
- reference: DOI:10.1055/s-0044-1788586
title: Brazilian consensus recommendations on the diagnosis and treatment of autoimmune encephalitis in the adult and pediatric populations
found_in:
- Autoimmune_Encephalitis-deep-research-falcon.md
findings:
- statement: Autoimmune encephalitis (AIE) is a group of inflammatory diseases characterized by the presence of antibodies against neuronal and glial antigens, leading to subacute psychiatric symptoms, memory complaints, and movement disorders.
supporting_text: Autoimmune encephalitis (AIE) is a group of inflammatory diseases characterized by the presence of antibodies against neuronal and glial antigens, leading to subacute psychiatric symptoms, memory complaints, and movement disorders.
evidence:
- reference: DOI:10.1055/s-0044-1788586
reference_title: Brazilian consensus recommendations on the diagnosis and treatment of autoimmune encephalitis in the adult and pediatric populations
supports: SUPPORT
evidence_source: OTHER
snippet: Autoimmune encephalitis (AIE) is a group of inflammatory diseases characterized by the presence of antibodies against neuronal and glial antigens, leading to subacute psychiatric symptoms, memory complaints, and movement disorders.
explanation: Deep research cited this publication as relevant literature for Autoimmune Encephalitis.
- reference: DOI:10.3389/fimmu.2023.1213532
title: 'Clinical characteristics and prognosis in patients with neuronal surface antibody-mediated autoimmune encephalitis: a single-center cohort study in China'
found_in:
- Autoimmune_Encephalitis-deep-research-falcon.md
findings:
- statement: 'Clinical characteristics and prognosis in patients with neuronal surface antibody-mediated autoimmune encephalitis: a single-center cohort study in China'
supporting_text: This retrospective observational study primarily aimed to analyse the clinical characteristics of patients with neuronal surface antibody-mediated autoimmune encephalitis (AE) in China and report their prognosis after immunotherapy.MethodsClinical characteristics, laboratory or imaging examinations, and treatment outcomes of 103 patients diagnosed with AE between 1 September 2014 and 31 December 2020 were collected.
evidence:
- reference: DOI:10.3389/fimmu.2023.1213532
reference_title: 'Clinical characteristics and prognosis in patients with neuronal surface antibody-mediated autoimmune encephalitis: a single-center cohort study in China'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: This retrospective observational study primarily aimed to analyse the clinical characteristics of patients with neuronal surface antibody-mediated autoimmune encephalitis (AE) in China and report their prognosis after immunotherapy.MethodsClinical characteristics, laboratory or imaging examinations, and treatment outcomes of 103 patients diagnosed with AE between 1 September 2014 and 31 December 2020 were collected.
explanation: Deep research cited this publication as relevant literature for Autoimmune Encephalitis.
Autoimmune encephalitis (AE; also written “autoimmune inflammatory encephalitis”, “autoimmune encephalopathy”, or “antibody-mediated encephalitis” depending on context) is a group of immune-mediated inflammatory brain disorders that typically present subacutely with neuropsychiatric symptoms, cognitive dysfunction, seizures, movement disorders, or altered level of consciousness, and are frequently associated with autoantibodies to neuronal cell-surface/synaptic or (in paraneoplastic neurologic syndromes) intracellular neuronal antigens. In a large real-world validation study, AE is described as being “associated with neuronal autoantibodies against extracellular antigens, which are directly pathogenic.” (steenhoven2023mimicsofautoimmune pages 1-2)
A practical case-definition used in modern guidelines is the 2016 Graus clinical criteria framework, which classifies patients as possible/probable/definite AE based on a subacute encephalopathy plus supportive MRI/CSF/EEG features, and then confirmation with syndrome-specific features and/or neural-specific antibody positivity. (orozco2023autoimmuneencephalitiscriteria pages 1-3, dutra2024brazilianconsensusrecommendations pages 4-5)
Within the evidence corpus retrieved for this run, explicit mappings to MONDO, Orphanet, MeSH, and ICD-10/ICD-11 identifiers for “autoimmune encephalitis” were not available; therefore these identifiers cannot be reliably populated from the cited sources here.
Commonly used terms in the literature captured in this run include: - Autoimmune encephalitis (AE) / Autoimmune inflammatory encephalitis (AIE) (dutra2024brazilianconsensusrecommendations pages 1-2) - Antibody-associated encephalitis / antibody-mediated encephalitis (steenhoven2023mimicsofautoimmune pages 1-2, kerstens2024autoimmuneencephalitisand pages 1-2) - Autoimmune encephalopathy (often used in broader clinical coding; discussed as “related autoimmune encephalopathy” in clinical practice series) (orozco2023autoimmuneencephalitiscriteria pages 1-3)
Evidence in this report is derived from: - Aggregated consensus guidelines (Canadian 2024; Brazilian 2024) (hahn2024canadianconsensusguidelines pages 8-9, dutra2024brazilianconsensusrecommendations pages 5-7) - Retrospective and nationwide observational cohorts (Mayo Clinic clinical practice study; Netherlands nationwide antibody-testing cohort) (orozco2023autoimmuneencephalitiscriteria pages 1-3, kerstens2024autoimmuneencephalitisand pages 1-2) - Diagnostic criteria validation and mimic studies (national referral center cohort) (steenhoven2023mimicsofautoimmune pages 1-2)
AE is typically conceptualized as antibody-associated immune-mediated encephalitis. Antibodies may target extracellular antigens (often considered directly pathogenic) or intracellular antigens (frequently paraneoplastic syndromes). (steenhoven2023mimicsofautoimmune pages 1-2, kerstens2024autoimmuneencephalitisand pages 1-2)
Neoplasm association varies by antibody subtype. Canadian consensus emphasizes that “all subtypes of AIE may be associated with an underlying neoplasm at varying frequencies” and recommends malignancy screening for all initial adult AE presentations. (hahn2024canadianconsensusguidelines pages 9-10)
Canadian guidance provides a malignancy-risk stratification by antibody (Table 4), e.g. high-risk antibodies (>70%) including Hu/ANNA1, Yo/PCA1, Ma2, KLHL11, etc.; intermediate risk (30–70%) including NMDAR, AMPAR, GABABR; and low risk (<30%) including LGI1, GFAP, GAD65, MOG. (hahn2024canadianconsensusguidelines pages 10-11)
Post-infectious immune mechanisms are recognized clinically (e.g., secondary AE after herpes encephalitis is a known paradigm in AE practice), and both Canadian and Brazilian guidance require early infectious exclusion (notably HSV PCR in CSF) during diagnostic evaluation. (dutra2024brazilianconsensusrecommendations pages 7-8, dutra2024brazilianconsensusrecommendations pages 5-7)
Immune checkpoint inhibitor (ICI)-related encephalitis is recognized as an AE phenotype and is treated with immunosuppressive strategies; Canadian consensus notes ICI therapy as a risk factor and discusses AE in the differential of acute encephalopathy. (hahn2024canadianconsensusguidelines pages 2-3)
Genetic predisposition is increasingly studied; however, in this run, detailed HLA/KIR evidence was retrieved but not processed into the evidence set with citable context IDs. Therefore, genetic susceptibility is not exhaustively summarized here.
Protective genetic or environmental factors were not explicitly reported in the retrieved, citable evidence for this run.
While environmental triggers (tumor, infection, ICI exposure) are recognized, explicit gene–environment interaction analyses were not available in the citable evidence retrieved for this run.
A Chinese cohort of neuronal-surface antibody AE (n=103) reported presenting frequencies: seizures 74.8%, psychiatric/behavior disorders 66.0%, cognitive deficits 51.5%, disturbances of consciousness 45.6%, and movement disorders/involuntary movements 26.2%. (huang2023clinicalcharacteristicsand pages 1-2)
In the Mayo Clinic real-world series of 538 adults (AE or related autoimmune encephalopathy), “possible AE” required subacute onset plus supportive features; among supportive features within possible AE (n=361), focal findings, seizures, supportive MRI, and CSF pleocytosis were common (as summarized in the paper’s abstract). (orozco2023autoimmuneencephalitiscriteria pages 1-3)
Based on the phenotype frequencies and guideline descriptions in the cited cohorts: - Seizures — HP:0001250 (huang2023clinicalcharacteristicsand pages 1-2) - Psychiatric symptoms / psychosis — HP:0000708 / HP:0000738 (huang2023clinicalcharacteristicsand pages 1-2) - Cognitive impairment — HP:0100543 (huang2023clinicalcharacteristicsand pages 1-2) - Altered mental status / impaired consciousness — HP:0001252 (huang2023clinicalcharacteristicsand pages 1-2) - Movement disorder / dyskinesia — HP:0100022 (huang2023clinicalcharacteristicsand pages 1-2) - CSF pleocytosis — HP:0002181 (dutra2024brazilianconsensusrecommendations pages 4-5)
Guidelines emphasize persistent neuropsychiatric and cognitive sequelae and the need to evaluate cognitive/functional outcomes using tools beyond mRS (e.g., CASE, MMSE, MoCA). (dutra2024brazilianconsensusrecommendations pages 8-10, hahn2024canadianconsensusguidelines pages 10-11)
Netherlands nationwide testing study lists major extracellular antigen (EA) targets including NMDAR, LGI1, CASPR2, GABABR, GABAAR, AMPAR, DPPX, GlyR, mGluR1, IgLON5, Tr/DNER and intracellular antigen (IA) targets including Hu/ANNA1, Yo/PCA1, CRMP5/CV2, Ri/ANNA2, Ma1/Ma2, amphiphysin, GAD65, GFAP, KLHL11. (kerstens2024autoimmuneencephalitisand pages 1-2)
In that nationwide cohort, the four most common AIE/PNS types were anti-NMDAR, anti-LGI1, anti-Hu, and anti-GAD65, comprising 364/578 (63.0%) of diagnoses. (kerstens2024autoimmuneencephalitisand pages 1-2)
AE is generally not a monogenic disease; causal Mendelian genes and variant-level pathogenicity (ClinVar-style) were not provided in the citable evidence retrieved in this run.
Not reported in the citable evidence retrieved in this run.
Workup guidelines emphasize exclusion of infectious encephalitis, specifically recommending CSF PCR testing for herpesviruses as part of AE evaluation and prior to/alongside immunotherapy. (dutra2024brazilianconsensusrecommendations pages 7-8, dutra2024brazilianconsensusrecommendations pages 5-7)
Neoplasm association is managed as a core environmental/biologic trigger; all adult AE presentations should undergo malignancy screening at diagnosis. (hahn2024canadianconsensusguidelines pages 9-10)
A practical mechanistic chain in antibody-mediated AE is: 1) Triggering exposure (e.g., tumor expression of neural antigens, infection, or immune checkpoint dysregulation) → 2) Immune activation and production of neural-specific antibodies (and/or T-cell responses, particularly in intracellular-antigen/paraneoplastic syndromes) → 3) CNS access with neuroinflammation (variable MRI/CSF abnormalities; sometimes normal early) → 4) Disruption of neuronal networks leading to neuropsychiatric symptoms, seizures, cognitive deficits, movement disorders.
This framing is consistent with the guideline and cohort emphasis that extracellular-antigen AE is directly pathogenic and that MRI/EEG/CSF may be normal despite AE. (steenhoven2023mimicsofautoimmune pages 1-2, hahn2024canadianconsensusguidelines pages 6-7)
Given the encephalitic phenotype and limbic predominance in multiple AE syndromes: - Brain — UBERON:0000955 - Hippocampus — UBERON:0001954 - Amygdala — UBERON:0001876
Primary affected system is the central nervous system (CNS), with presentations including limbic encephalitis phenotypes and diffuse encephalopathy. (orozco2023autoimmuneencephalitiscriteria pages 1-3, hahn2024canadianconsensusguidelines pages 10-11)
The evidence base in this run does not provide histopathology-level cell targeting across AE subtypes; however, antibody-associated mechanisms imply neuronal synaptic/extracellular target involvement for many EA antibodies and broader neuroinflammatory involvement in some cases. (kerstens2024autoimmuneencephalitisand pages 1-2, steenhoven2023mimicsofautoimmune pages 1-2)
Core criteria and guidelines define onset as subacute, typically rapid progression within <3 months for possible AE. (dutra2024brazilianconsensusrecommendations pages 4-5)
Relapse is a recognized course feature. Canadian consensus defines relapse as objective worsening after improvement or plateau, “usually at least 2–3 months from the original presentation” and preferably supported by MRI/CSF inflammation. (hahn2024canadianconsensusguidelines pages 12-13)
A Netherlands nationwide retrospective cohort (2016–2021) estimated AE/paraneoplastic neurologic syndrome (AIE/PNS) incidence increasing from 4.70 per million person-years (2016) to 5.76 per million person-years (2021), with overall incidence 5.57 per million person-years (95% CI 5.13–6.05). (kerstens2024autoimmuneencephalitisand pages 1-2)
The Canadian consensus notes antibody-specific demographic patterns (e.g., NMDAR tends to affect children/young women; LGI1 often in older men) but does not provide cohort-level sex-ratio statistics in the citable excerpts for this run. (hahn2024canadianconsensusguidelines pages 2-3)
The Graus 2016 “possible AE” criteria (adult) are a widely implemented entry step: subacute onset plus ≥1 supportive feature and exclusion of alternative causes. (orozco2023autoimmuneencephalitiscriteria pages 1-3, dutra2024brazilianconsensusrecommendations pages 4-5)
A structured diagnostic workflow is supported by both Brazilian and Canadian consensus: - Brain MRI, EEG, CSF analysis including IgG index and oligoclonal bands (OCBs). (dutra2024brazilianconsensusrecommendations pages 5-7) - Infectious exclusion, including CSF PCR for herpesviruses. (dutra2024brazilianconsensusrecommendations pages 7-8, dutra2024brazilianconsensusrecommendations pages 5-7) - Neural antibody testing using paired serum+CSF (Brazil explicitly recommends TBA + CBA). (dutra2024brazilianconsensusrecommendations pages 5-7)
A concise, evidence-backed diagnostic criteria/performance and workflow summary is provided in the table artifact below.
| Topic | Key points (with numbers) | Evidence type | Source (authors/year/journal) | URL |
|---|---|---|---|---|
| Graus 2016 possible AE criteria | Adult possible AE requires all 3: (1) subacute onset, rapid progression in <3 months, of working memory deficits/altered mental status/psychiatric symptoms; (2) ≥1 supportive feature: new focal CNS findings, unexplained seizures, CSF pleocytosis, or MRI suggestive of encephalitis; (3) reasonable exclusion of alternative causes. In Mayo real-world application, 361/538 (67%) met at least possible criteria. (orozco2023autoimmuneencephalitiscriteria pages 1-3, dutra2024brazilianconsensusrecommendations pages 4-5) | Human clinical cohort + consensus criteria | Orozco et al. 2023, Neurology Clinical Practice; Dutra et al. 2024, Arquivos de Neuro-Psiquiatria | https://doi.org/10.1212/cpj.0000000000200151 ; https://doi.org/10.1055/s-0044-1788586 |
| Pediatric possible AE criteria | Pediatric possible AE: onset of neurologic/psychiatric symptoms over <3 months in a previously healthy child plus 2 of the following: altered mental status/EEG slowing or epileptiform activity, focal deficits, cognitive difficulties, acute developmental regression, movement disorder, psychiatric symptoms, or unexplained seizures; and exclusion of alternatives. (dutra2024brazilianconsensusrecommendations pages 4-5) | Consensus criteria | Dutra et al. 2024, Arquivos de Neuro-Psiquiatria | https://doi.org/10.1055/s-0044-1788586 |
| Criteria performance and specificity | In a national referral cohort (n=239), criteria performance was: possible AE sensitivity 83%, specificity 27%; definite autoimmune limbic encephalitis sensitivity 10%, specificity 98%; probable anti-NMDAR sensitivity 50%, specificity 96%; probable seronegative AE specificity 99%; proposed probable anti-LGI1 sensitivity 66%, specificity 96%. Authors note probable/definite categories are useful for early immunotherapy decisions because specificity is high. (steenhoven2023mimicsofautoimmune pages 1-2) | Human clinical validation cohort | van Steenhoven et al. 2023, Neurology Neuroimmunology & Neuroinflammation | https://doi.org/10.1212/nxi.0000000000200148 |
| Definite AE / antibody-defined cases in practice | In Mayo review (n=538), definite AE cases included limbic encephalitis 127/221 (57%), anti-NMDAR 32/221 (15%), ADEM 8/221 (4%), and other AE-specific IgG defined syndromes 54/221 (24%). Most common definite AE-IgGs: LGI1 76 (34%), NMDA-R 32 (16%), high-titer GAD65 23 (12%). Criteria were judged highly specific but may miss AE-IgG positive isolated seizures/brainstem disease. (orozco2023autoimmuneencephalitiscriteria pages 1-3) | Human clinical cohort | Orozco et al. 2023, Neurology Clinical Practice | https://doi.org/10.1212/cpj.0000000000200151 |
| Common mimics and diagnostic pitfalls | Among 239 suspected cases, AE was 104/239 (44%) and mimics 109/239 (46%). Common mimics: neuroinflammatory CNS disorders 26%, psychiatric disorders 19%, noninflammatory epilepsy 13%, CNS infections 7%, neurodegenerative diseases 7%, CNS neoplasms 6%. Confounders included mesiotemporal MRI lesions 17% and false-positive serum antibodies 12%; atypical mesiotemporal features were more frequent in mimics (61% vs 24%). (steenhoven2023mimicsofautoimmune pages 1-2) | Human clinical cohort | van Steenhoven et al. 2023, Neurology Neuroimmunology & Neuroinflammation | https://doi.org/10.1212/nxi.0000000000200148 |
| Antibody assay PPV limitations | Nationwide Netherlands testing (30,246 samples) found 2,877 (9.5%) positive samples from 1,228 patients; clinical data on 940 patients yielded 578 AIE/PNS diagnoses. Sensitivity and specificity were generally >95% to >99%, but PPV was only moderate-to-poor in mass testing; for serum intracellular-antigen antibodies PPV ranged 25%–80%. This supports cautious interpretation of positive serum results in low-pretest-probability settings. (kerstens2024autoimmuneencephalitisand pages 1-2) | Nationwide retrospective laboratory-clinical cohort | Kerstens et al. 2024, Neurology Neuroimmunology & Neuroinflammation | https://doi.org/10.1212/nxi.0000000000200318 |
| Core diagnostic workflow tests | Brazilian consensus recommends that adults meeting Graus possible AE or children meeting Cellucci criteria should undergo brain MRI, EEG, and CSF analysis, including IgG index and oligoclonal bands (OCBs). These are baseline tests before/alongside antibody evaluation. (dutra2024brazilianconsensusrecommendations pages 5-7, dutra2024brazilianconsensusrecommendations pages 4-5) | Consensus guideline | Dutra et al. 2024, Arquivos de Neuro-Psiquiatria | https://doi.org/10.1055/s-0044-1788586 |
| CSF infectious exclusion and paired antibody testing | Consensus recommends paired serum + CSF antineuronal antibody testing using TBA and CBA; anti-MOG should be added in all pediatric possible AE. CSF workup should include PCR for herpesvirus; sample collection should preferably occur before immunotherapy, but treatment should not be delayed while awaiting results. (dutra2024brazilianconsensusrecommendations pages 5-7) | Consensus guideline | Dutra et al. 2024, Arquivos de Neuro-Psiquiatria | https://doi.org/10.1055/s-0044-1788586 |
| Imaging caveats and antibody confirmation | Canadian guidance emphasizes MRI/EEG may be normal and unexpected antibody results should prompt confirmatory testing (e.g., tissue indirect immunofluorescence/immunohistochemistry). Initial screening should not wait for antibody results. (hahn2024canadianconsensusguidelines pages 9-10, hahn2024canadianconsensusguidelines pages 10-11) | Consensus guideline | Hahn et al. 2024, Canadian Journal of Neurological Sciences | https://doi.org/10.1017/cjn.2024.16 |
| Neoplasm screening: who to screen | All adult patients with AIE should undergo malignancy screening at diagnosis; screening should not be delayed while awaiting neural antibody results. Screening should also be considered at relapse. (hahn2024canadianconsensusguidelines pages 9-10, hahn2024canadianconsensusguidelines pages 10-11) | Consensus guideline | Hahn et al. 2024, Canadian Journal of Neurological Sciences | https://doi.org/10.1017/cjn.2024.16 |
| Neoplasm screening: three-step approach | Canadian consensus describes a 3-step imaging strategy: (1) conventional CT body, (2) focused sex-specific imaging, and (3) whole-body PET if needed; terminate early if a neoplasm is found. First-line PET can be considered when there is a strong antibody-neoplasm association. Pelvic US or MRI is preferred over PET for ovarian teratoma. (hahn2024canadianconsensusguidelines pages 9-10, hahn2024canadianconsensusguidelines pages 10-11) | Consensus guideline | Hahn et al. 2024, Canadian Journal of Neurological Sciences | https://doi.org/10.1017/cjn.2024.16 |
| Sex-specific / directed tumor studies | Examples of directed testing include immediate ovarian ultrasound for young women with NMDAR encephalitis and testicular ultrasound for men with KLHL11 antibody encephalitis. Brazilian consensus similarly recommends CT chest/abdomen/pelvis plus sex-specific studies such as transvaginal US/mammography for women and scrotal US for men. (hahn2024canadianconsensusguidelines pages 10-11, dutra2024brazilianconsensusrecommendations pages 5-7) | Consensus guideline | Hahn et al. 2024, Canadian Journal of Neurological Sciences; Dutra et al. 2024, Arquivos de Neuro-Psiquiatria | https://doi.org/10.1017/cjn.2024.16 ; https://doi.org/10.1055/s-0044-1788586 |
| Follow-up tumor surveillance | If initial screening is negative, Canadian guidance recommends follow-up screening in patients with intermediate- or high-risk antibodies; for such antibodies, repeat screening every 3–6 months for at least 2 years is recommended. Antibody-negative patients with high-risk phenotypes (e.g., limbic encephalitis, refractory/relapsing disease, malignancy risk factors) may also merit repeat screening. (hahn2024canadianconsensusguidelines pages 9-10, hahn2024canadianconsensusguidelines pages 10-11) | Consensus guideline | Hahn et al. 2024, Canadian Journal of Neurological Sciences | https://doi.org/10.1017/cjn.2024.16 |
| Malignancy-risk antibody categories | Canadian Table 4 classifies tumor risk: high-risk >70% (e.g., Hu/ANNA-1, CV2/CRMP5, Ma2/Ma, KLHL11, Yo/PCA-1), intermediate 30–70% (e.g., AMPAR, GABABR, mGluR5, NMDAR, CASPR2 in Morvan syndrome, GABAAR), and low-risk <30% (e.g., GFAP, GAD65, LGI1, DPPX, GlyR, MOG, AQP4, mGluR1). (hahn2024canadianconsensusguidelines pages 10-11) | Consensus guideline | Hahn et al. 2024, Canadian Journal of Neurological Sciences | https://doi.org/10.1017/cjn.2024.16 |
Table: This table summarizes evidence-based autoimmune encephalitis diagnostic criteria, common pitfalls, core testing workflow, and neoplasm screening recommendations from recent validation studies and 2024 consensus guidelines. It is useful as a compact reference for applying Graus/Cellucci criteria, interpreting antibody results cautiously, and structuring tumor search in suspected AE.
In a real-world validation/mimic cohort (n=239), “possible AE” criteria had sensitivity 83% and specificity 27%, reflecting usefulness as an entry criterion but a high false-positive burden; “definite autoimmune limbic encephalitis” had specificity 98%, and “probable anti-NMDAR” had specificity 96%. (steenhoven2023mimicsofautoimmune pages 1-2)
Key pitfalls include: - False-positive serum antibodies (reported in 12% of the mimic/AE referral cohort). (steenhoven2023mimicsofautoimmune pages 1-2) - In mass-testing settings, PPV can be only modest: in the Netherlands nationwide antibody-testing cohort, serum intracellular-antigen antibody PPVs ranged 25%–80%, despite high sensitivity/specificity for most assays. (kerstens2024autoimmuneencephalitisand pages 1-2)
Canadian consensus states FDG-PET can be more sensitive than MRI in AE (reported 87% vs 25–50% sensitivity) but warns that PET findings can be nonspecific and should not be used alone. (hahn2024canadianconsensusguidelines pages 6-7, hahn2024canadianconsensusguidelines pages 12-13)
Canadian consensus recommends malignancy screening for all adult AE at diagnosis and describes a 3-step imaging strategy (CT body → sex-specific imaging → whole-body PET if needed), with follow-up screening focused on intermediate/high-risk antibodies. (hahn2024canadianconsensusguidelines pages 9-10, hahn2024canadianconsensusguidelines pages 10-11)
The neoplasm screening protocol figure from the Canadian guideline is shown here. (hahn2024canadianconsensusguidelines media d7e73b99)
In the Chinese cohort (n=103), most patients achieved favorable function at last follow-up: 78 had good prognosis (mRS 0–2) vs 21 with poor prognosis (mRS 3–6); anti-GABABR encephalitis had worse outcomes than other AE subtypes. (huang2023clinicalcharacteristicsand pages 1-2)
In the same cohort, elevated neutrophil-to-lymphocyte ratio (NLR) and tumor presence were independent predictors of poor prognosis; a model combining these achieved AUC 0.847 (95% CI 0.733–0.961). (huang2023clinicalcharacteristicsand pages 1-2)
Canadian consensus summarizes retrospective relapse rates in NMDAR/LGI1/CASPR2 encephalitis as 10–41% and notes relapses may be similar, milder, or with a different core syndrome. (hahn2024canadianconsensusguidelines pages 12-13)
Brazilian consensus explicitly states: “Treatment should be started within the first 4 weeks of symptoms,” and that initiation “should not be delayed while waiting for” antibody results. (dutra2024brazilianconsensusrecommendations pages 1-2, dutra2024brazilianconsensusrecommendations pages 5-7)
Brazilian consensus: first-line is methylprednisolone + IVIG or methylprednisolone + plasmapheresis, with typical IVIG and steroid dosing specified (e.g., IVIG 2 g/kg over 2–5 days; IV methylprednisolone 1,000 mg daily for 3–5 days in adults). (dutra2024brazilianconsensusrecommendations pages 8-10, dutra2024brazilianconsensusrecommendations pages 5-7)
Canadian consensus: severe AE should receive high-dose corticosteroids with IVIG or plasma exchange as initial therapy; mild/moderate cases may consider steroid monotherapy with specialist input. (hahn2024canadianconsensusguidelines pages 9-10)
The Canadian guideline treatment algorithm figure is shown here. (hahn2024canadianconsensusguidelines media aed80ffe)
Brazilian consensus defines “satisfactory clinical response” as improvement within 10–14 days; lack of partial improvement within 14 days should prompt second-line therapy. (dutra2024brazilianconsensusrecommendations pages 5-7)
Canadian consensus defines first-line failure as no improvement/worsening at 5–10 days in severe AE and 2–4 weeks in mild/moderate AE. (hahn2024canadianconsensusguidelines pages 8-9)
Second-line choices are antibody-contextual: - Cell-surface antibody AE or antibody-negative AE: rituximab favored for efficacy/safety. (hahn2024canadianconsensusguidelines pages 8-9) - High-risk paraneoplastic/intracellular antibodies: cyclophosphamide preferentially used. (hahn2024canadianconsensusguidelines pages 8-9)
Canadian and Brazilian guidance list tocilizumab and bortezomib as third-line/experimental options for cases refractory to second-line therapy, with specialist involvement recommended. (hahn2024canadianconsensusguidelines pages 9-10, dutra2024brazilianconsensusrecommendations pages 5-7)
Seizures in AE are commonly acute symptomatic; Brazilian consensus notes antiseizure medications may be weaned after the acute stage when stable. (dutra2024brazilianconsensusrecommendations pages 1-2)
Primary prevention is not established for most AE syndromes given heterogeneous triggers. Secondary/tertiary prevention is emphasized via: - Early diagnosis and early immunotherapy to reduce morbidity and long-term deficits. (dutra2024brazilianconsensusrecommendations pages 5-7, hahn2024canadianconsensusguidelines pages 9-10) - Tumor screening and treatment/removal when present (paraneoplastic prevention of ongoing antigenic drive). (hahn2024canadianconsensusguidelines pages 9-10)
Naturally occurring AE-like antibody-mediated encephalitis in non-human species was not addressed in the citable evidence retrieved in this run.
Animal/model system evidence was not present in the citable evidence retrieved in this run.
References
(steenhoven2023mimicsofautoimmune pages 1-2): Robin W. Van Steenhoven, Juna M. de Vries, Arlette L. Bruijstens, Manuela Paunovic, Mariska M. Nagtzaam, Suzanne C. Franken, Anna E. Bastiaansen, Marienke A. De Bruijn, Agnes Van Sonderen, Marco W.J. Schreurs, Mayke Gardeniers, Robert M. Verdijk, Rutger K. Balvers, Peter A. Sillevis Smitt, Rinze F. Neuteboom, and Maarten J. Titulaer. Mimics of autoimmune encephalitis. Neurology Neuroimmunology & Neuroinflammation, Nov 2023. URL: https://doi.org/10.1212/nxi.0000000000200148, doi:10.1212/nxi.0000000000200148. This article has 72 citations.
(orozco2023autoimmuneencephalitiscriteria pages 1-3): Emma Orozco, Cristina Valencia-Sanchez, Jeffrey Britton, Divyanshu Dubey, Eoin P. Flanagan, A. Sebastian Lopez-Chiriboga, Nicholas Zalewski, Anastasia Zekeridou, Sean J. Pittock, and Andrew McKeon. Autoimmune encephalitis criteria in clinical practice. Neurology Clinical Practice, Jun 2023. URL: https://doi.org/10.1212/cpj.0000000000200151, doi:10.1212/cpj.0000000000200151. This article has 65 citations.
(dutra2024brazilianconsensusrecommendations pages 4-5): Lívia Almeida Dutra, Pedro Victor de Castro Silva, João Henrique Fregadolli Ferreira, Alexandre Coelho Marques, Fabio Fieni Toso, Claudia Cristina Ferreira Vasconcelos, Doralina Guimarães Brum, Samira Luisa dos Apóstolos Pereira, Tarso Adoni, Leticia Januzi de Almeida Rocha, Leticia Pereira de Brito Sampaio, Nise Alessandra de Carvalho Sousa, Renata Barbosa Paolilo, Angélica Dal Pizzol, Bruna Klein da Costa, Caio César Diniz Disserol, Camila Pupe, Daniel Almeida do Valle, Denise Sisterolli Diniz, Fabiano Ferreira de Abrantes, Felipe da Rocha Schmidt, Fernando Cendes, Francisco Tomaz Meneses de Oliveira, Gabriela Joca Martins, Guilherme Diogo Silva, Katia Lin, Lécio Figueira Pinto, Mara Lúcia Schimtz Ferreira Santos, Marcus Vinícius Magno Gonçalves, Mariana Braatz Krueger, Michel Elyas Jung Haziot, Orlando Graziani Povoas Barsottini, Osvaldo José Moreira do Nascimento, Paulo Ribeiro Nóbrega, Priscilla Mara Proveti, Raphael Machado do Castilhos, Vanessa Daccach, and Felipe von Glehn. Brazilian consensus recommendations on the diagnosis and treatment of autoimmune encephalitis in the adult and pediatric populations. Arquivos de Neuro-Psiquiatria, 82:001-015, Jul 2024. URL: https://doi.org/10.1055/s-0044-1788586, doi:10.1055/s-0044-1788586. This article has 10 citations and is from a peer-reviewed journal.
(dutra2024brazilianconsensusrecommendations pages 1-2): Lívia Almeida Dutra, Pedro Victor de Castro Silva, João Henrique Fregadolli Ferreira, Alexandre Coelho Marques, Fabio Fieni Toso, Claudia Cristina Ferreira Vasconcelos, Doralina Guimarães Brum, Samira Luisa dos Apóstolos Pereira, Tarso Adoni, Leticia Januzi de Almeida Rocha, Leticia Pereira de Brito Sampaio, Nise Alessandra de Carvalho Sousa, Renata Barbosa Paolilo, Angélica Dal Pizzol, Bruna Klein da Costa, Caio César Diniz Disserol, Camila Pupe, Daniel Almeida do Valle, Denise Sisterolli Diniz, Fabiano Ferreira de Abrantes, Felipe da Rocha Schmidt, Fernando Cendes, Francisco Tomaz Meneses de Oliveira, Gabriela Joca Martins, Guilherme Diogo Silva, Katia Lin, Lécio Figueira Pinto, Mara Lúcia Schimtz Ferreira Santos, Marcus Vinícius Magno Gonçalves, Mariana Braatz Krueger, Michel Elyas Jung Haziot, Orlando Graziani Povoas Barsottini, Osvaldo José Moreira do Nascimento, Paulo Ribeiro Nóbrega, Priscilla Mara Proveti, Raphael Machado do Castilhos, Vanessa Daccach, and Felipe von Glehn. Brazilian consensus recommendations on the diagnosis and treatment of autoimmune encephalitis in the adult and pediatric populations. Arquivos de Neuro-Psiquiatria, 82:001-015, Jul 2024. URL: https://doi.org/10.1055/s-0044-1788586, doi:10.1055/s-0044-1788586. This article has 10 citations and is from a peer-reviewed journal.
(kerstens2024autoimmuneencephalitisand pages 1-2): Jeroen Kerstens, Marco W.J. Schreurs, Juna M. de Vries, Rinze F. Neuteboom, Juliette Brenner, Yvette S. Crijnen, Robin W. van Steenhoven, Marienke A.A.M. de Bruijn, Agnes van Sonderen, Marleen H. van Coevorden-Hameete, Anna E.M. Bastiaansen, Marie R. Vermeiren, Jan G.M.C. Damoiseaux, Henny G. Otten, Catharina J.M. Frijns, Bob Meek, Anouk C.M. Platteel, Alina van de Mortel, Cathérine C.S. Delnooz, Maarten A.C. Broeren, Marcel M. Verbeek, Erik I. Hoff, Sanae Boukhrissi, Suzanne C. Franken, Mariska M.P. Nagtzaam, Manuela Paunovic, Sharon Veenbergen, Peter A.E. Sillevis Smitt, and Maarten J. Titulaer. Autoimmune encephalitis and paraneoplastic neurologic syndromes. Neurology Neuroimmunology & Neuroinflammation, Nov 2024. URL: https://doi.org/10.1212/nxi.0000000000200318, doi:10.1212/nxi.0000000000200318. This article has 29 citations.
(hahn2024canadianconsensusguidelines pages 8-9): Christopher Hahn, Adrian Budhram, Katayoun Alikhani, Nasser AlOhaly, Grayson Beecher, Gregg Blevins, John Brooks, Robert Carruthers, Jacynthe Comtois, Juthaporn Cowan, Paula de Robles, Julien Hébert, Ronak K. Kapadia, Sarah Lapointe, Aaron Mackie, Warren Mason, Brienne McLane, Alexandra Muccilli, Ilia Poliakov, Penelope Smyth, Kimberly G. Williams, Christopher Uy, and Jennifer A. McCombe. Canadian consensus guidelines for the diagnosis and treatment of autoimmune encephalitis in adults. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 51:734-754, Feb 2024. URL: https://doi.org/10.1017/cjn.2024.16, doi:10.1017/cjn.2024.16. This article has 33 citations.
(dutra2024brazilianconsensusrecommendations pages 5-7): Lívia Almeida Dutra, Pedro Victor de Castro Silva, João Henrique Fregadolli Ferreira, Alexandre Coelho Marques, Fabio Fieni Toso, Claudia Cristina Ferreira Vasconcelos, Doralina Guimarães Brum, Samira Luisa dos Apóstolos Pereira, Tarso Adoni, Leticia Januzi de Almeida Rocha, Leticia Pereira de Brito Sampaio, Nise Alessandra de Carvalho Sousa, Renata Barbosa Paolilo, Angélica Dal Pizzol, Bruna Klein da Costa, Caio César Diniz Disserol, Camila Pupe, Daniel Almeida do Valle, Denise Sisterolli Diniz, Fabiano Ferreira de Abrantes, Felipe da Rocha Schmidt, Fernando Cendes, Francisco Tomaz Meneses de Oliveira, Gabriela Joca Martins, Guilherme Diogo Silva, Katia Lin, Lécio Figueira Pinto, Mara Lúcia Schimtz Ferreira Santos, Marcus Vinícius Magno Gonçalves, Mariana Braatz Krueger, Michel Elyas Jung Haziot, Orlando Graziani Povoas Barsottini, Osvaldo José Moreira do Nascimento, Paulo Ribeiro Nóbrega, Priscilla Mara Proveti, Raphael Machado do Castilhos, Vanessa Daccach, and Felipe von Glehn. Brazilian consensus recommendations on the diagnosis and treatment of autoimmune encephalitis in the adult and pediatric populations. Arquivos de Neuro-Psiquiatria, 82:001-015, Jul 2024. URL: https://doi.org/10.1055/s-0044-1788586, doi:10.1055/s-0044-1788586. This article has 10 citations and is from a peer-reviewed journal.
(hahn2024canadianconsensusguidelines pages 9-10): Christopher Hahn, Adrian Budhram, Katayoun Alikhani, Nasser AlOhaly, Grayson Beecher, Gregg Blevins, John Brooks, Robert Carruthers, Jacynthe Comtois, Juthaporn Cowan, Paula de Robles, Julien Hébert, Ronak K. Kapadia, Sarah Lapointe, Aaron Mackie, Warren Mason, Brienne McLane, Alexandra Muccilli, Ilia Poliakov, Penelope Smyth, Kimberly G. Williams, Christopher Uy, and Jennifer A. McCombe. Canadian consensus guidelines for the diagnosis and treatment of autoimmune encephalitis in adults. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 51:734-754, Feb 2024. URL: https://doi.org/10.1017/cjn.2024.16, doi:10.1017/cjn.2024.16. This article has 33 citations.
(hahn2024canadianconsensusguidelines pages 10-11): Christopher Hahn, Adrian Budhram, Katayoun Alikhani, Nasser AlOhaly, Grayson Beecher, Gregg Blevins, John Brooks, Robert Carruthers, Jacynthe Comtois, Juthaporn Cowan, Paula de Robles, Julien Hébert, Ronak K. Kapadia, Sarah Lapointe, Aaron Mackie, Warren Mason, Brienne McLane, Alexandra Muccilli, Ilia Poliakov, Penelope Smyth, Kimberly G. Williams, Christopher Uy, and Jennifer A. McCombe. Canadian consensus guidelines for the diagnosis and treatment of autoimmune encephalitis in adults. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 51:734-754, Feb 2024. URL: https://doi.org/10.1017/cjn.2024.16, doi:10.1017/cjn.2024.16. This article has 33 citations.
(dutra2024brazilianconsensusrecommendations pages 7-8): Lívia Almeida Dutra, Pedro Victor de Castro Silva, João Henrique Fregadolli Ferreira, Alexandre Coelho Marques, Fabio Fieni Toso, Claudia Cristina Ferreira Vasconcelos, Doralina Guimarães Brum, Samira Luisa dos Apóstolos Pereira, Tarso Adoni, Leticia Januzi de Almeida Rocha, Leticia Pereira de Brito Sampaio, Nise Alessandra de Carvalho Sousa, Renata Barbosa Paolilo, Angélica Dal Pizzol, Bruna Klein da Costa, Caio César Diniz Disserol, Camila Pupe, Daniel Almeida do Valle, Denise Sisterolli Diniz, Fabiano Ferreira de Abrantes, Felipe da Rocha Schmidt, Fernando Cendes, Francisco Tomaz Meneses de Oliveira, Gabriela Joca Martins, Guilherme Diogo Silva, Katia Lin, Lécio Figueira Pinto, Mara Lúcia Schimtz Ferreira Santos, Marcus Vinícius Magno Gonçalves, Mariana Braatz Krueger, Michel Elyas Jung Haziot, Orlando Graziani Povoas Barsottini, Osvaldo José Moreira do Nascimento, Paulo Ribeiro Nóbrega, Priscilla Mara Proveti, Raphael Machado do Castilhos, Vanessa Daccach, and Felipe von Glehn. Brazilian consensus recommendations on the diagnosis and treatment of autoimmune encephalitis in the adult and pediatric populations. Arquivos de Neuro-Psiquiatria, 82:001-015, Jul 2024. URL: https://doi.org/10.1055/s-0044-1788586, doi:10.1055/s-0044-1788586. This article has 10 citations and is from a peer-reviewed journal.
(hahn2024canadianconsensusguidelines pages 2-3): Christopher Hahn, Adrian Budhram, Katayoun Alikhani, Nasser AlOhaly, Grayson Beecher, Gregg Blevins, John Brooks, Robert Carruthers, Jacynthe Comtois, Juthaporn Cowan, Paula de Robles, Julien Hébert, Ronak K. Kapadia, Sarah Lapointe, Aaron Mackie, Warren Mason, Brienne McLane, Alexandra Muccilli, Ilia Poliakov, Penelope Smyth, Kimberly G. Williams, Christopher Uy, and Jennifer A. McCombe. Canadian consensus guidelines for the diagnosis and treatment of autoimmune encephalitis in adults. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 51:734-754, Feb 2024. URL: https://doi.org/10.1017/cjn.2024.16, doi:10.1017/cjn.2024.16. This article has 33 citations.
(huang2023clinicalcharacteristicsand pages 1-2): Teng Huang, Fei Liu, Baojie Wang, Chunjuan Wang, Maolin Hao, and Shougang Guo. Clinical characteristics and prognosis in patients with neuronal surface antibody-mediated autoimmune encephalitis: a single-center cohort study in china. Frontiers in Immunology, Dec 2023. URL: https://doi.org/10.3389/fimmu.2023.1213532, doi:10.3389/fimmu.2023.1213532. This article has 17 citations and is from a peer-reviewed journal.
(dutra2024brazilianconsensusrecommendations pages 8-10): Lívia Almeida Dutra, Pedro Victor de Castro Silva, João Henrique Fregadolli Ferreira, Alexandre Coelho Marques, Fabio Fieni Toso, Claudia Cristina Ferreira Vasconcelos, Doralina Guimarães Brum, Samira Luisa dos Apóstolos Pereira, Tarso Adoni, Leticia Januzi de Almeida Rocha, Leticia Pereira de Brito Sampaio, Nise Alessandra de Carvalho Sousa, Renata Barbosa Paolilo, Angélica Dal Pizzol, Bruna Klein da Costa, Caio César Diniz Disserol, Camila Pupe, Daniel Almeida do Valle, Denise Sisterolli Diniz, Fabiano Ferreira de Abrantes, Felipe da Rocha Schmidt, Fernando Cendes, Francisco Tomaz Meneses de Oliveira, Gabriela Joca Martins, Guilherme Diogo Silva, Katia Lin, Lécio Figueira Pinto, Mara Lúcia Schimtz Ferreira Santos, Marcus Vinícius Magno Gonçalves, Mariana Braatz Krueger, Michel Elyas Jung Haziot, Orlando Graziani Povoas Barsottini, Osvaldo José Moreira do Nascimento, Paulo Ribeiro Nóbrega, Priscilla Mara Proveti, Raphael Machado do Castilhos, Vanessa Daccach, and Felipe von Glehn. Brazilian consensus recommendations on the diagnosis and treatment of autoimmune encephalitis in the adult and pediatric populations. Arquivos de Neuro-Psiquiatria, 82:001-015, Jul 2024. URL: https://doi.org/10.1055/s-0044-1788586, doi:10.1055/s-0044-1788586. This article has 10 citations and is from a peer-reviewed journal.
(hahn2024canadianconsensusguidelines pages 6-7): Christopher Hahn, Adrian Budhram, Katayoun Alikhani, Nasser AlOhaly, Grayson Beecher, Gregg Blevins, John Brooks, Robert Carruthers, Jacynthe Comtois, Juthaporn Cowan, Paula de Robles, Julien Hébert, Ronak K. Kapadia, Sarah Lapointe, Aaron Mackie, Warren Mason, Brienne McLane, Alexandra Muccilli, Ilia Poliakov, Penelope Smyth, Kimberly G. Williams, Christopher Uy, and Jennifer A. McCombe. Canadian consensus guidelines for the diagnosis and treatment of autoimmune encephalitis in adults. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 51:734-754, Feb 2024. URL: https://doi.org/10.1017/cjn.2024.16, doi:10.1017/cjn.2024.16. This article has 33 citations.
(hahn2024canadianconsensusguidelines pages 12-13): Christopher Hahn, Adrian Budhram, Katayoun Alikhani, Nasser AlOhaly, Grayson Beecher, Gregg Blevins, John Brooks, Robert Carruthers, Jacynthe Comtois, Juthaporn Cowan, Paula de Robles, Julien Hébert, Ronak K. Kapadia, Sarah Lapointe, Aaron Mackie, Warren Mason, Brienne McLane, Alexandra Muccilli, Ilia Poliakov, Penelope Smyth, Kimberly G. Williams, Christopher Uy, and Jennifer A. McCombe. Canadian consensus guidelines for the diagnosis and treatment of autoimmune encephalitis in adults. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 51:734-754, Feb 2024. URL: https://doi.org/10.1017/cjn.2024.16, doi:10.1017/cjn.2024.16. This article has 33 citations.
(hahn2024canadianconsensusguidelines media d7e73b99): Christopher Hahn, Adrian Budhram, Katayoun Alikhani, Nasser AlOhaly, Grayson Beecher, Gregg Blevins, John Brooks, Robert Carruthers, Jacynthe Comtois, Juthaporn Cowan, Paula de Robles, Julien Hébert, Ronak K. Kapadia, Sarah Lapointe, Aaron Mackie, Warren Mason, Brienne McLane, Alexandra Muccilli, Ilia Poliakov, Penelope Smyth, Kimberly G. Williams, Christopher Uy, and Jennifer A. McCombe. Canadian consensus guidelines for the diagnosis and treatment of autoimmune encephalitis in adults. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 51:734-754, Feb 2024. URL: https://doi.org/10.1017/cjn.2024.16, doi:10.1017/cjn.2024.16. This article has 33 citations.
(hahn2024canadianconsensusguidelines media aed80ffe): Christopher Hahn, Adrian Budhram, Katayoun Alikhani, Nasser AlOhaly, Grayson Beecher, Gregg Blevins, John Brooks, Robert Carruthers, Jacynthe Comtois, Juthaporn Cowan, Paula de Robles, Julien Hébert, Ronak K. Kapadia, Sarah Lapointe, Aaron Mackie, Warren Mason, Brienne McLane, Alexandra Muccilli, Ilia Poliakov, Penelope Smyth, Kimberly G. Williams, Christopher Uy, and Jennifer A. McCombe. Canadian consensus guidelines for the diagnosis and treatment of autoimmune encephalitis in adults. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 51:734-754, Feb 2024. URL: https://doi.org/10.1017/cjn.2024.16, doi:10.1017/cjn.2024.16. This article has 33 citations.